Blood Coagulation & Fibrinolysis · 2021 · 17 citations · 23 references
MedicineGeneticsMolecular BiologyHemostasisHuman GeneticsMedical GeneticsCoagulation AbnormalitiesCoagulation CascadeCoagulation DisordersCoagulation PhysiologyThrombin GenerationThrombosisCoagulationCoagulation BiomarkersCoagulation DysregulationHotspot MutationsInherited Coagulation Factor DeficienciesPlasminogen ActivatorsTissue Factor ActivationTurbidity
Turbidity analysis is widely used as a quantitative technique in hereditary dysfibrinogenemia. We aimed to compare several coagulation triggers in hereditary dysfibrinogenemia and control plasmas. We included 20 patients with hereditary dysfibrinogenemia, 19 with hotspot mutations Aα Arg35His (n = 9), Aα Arg35Cys (n = 2), γ Arg301His (n = 6), γ Arg301Cys (n = 2), and one with Aα Phe27Tyr, and a commercial pooled normal plasma. Fibrin polymerization was activated by bovine or human thrombin or tissue factor (TF), in the presence or absence of tissue type plasminogen activator. The lag time (min), slope (mOD/s), maximum absorbance (MaxAbs, mOD), and area under the curve (AUCp, OD s) were calculated from the fibrin polymerization curves and the time for 50% clot degradation (T50, min), AUCf (OD s) and the overall fibrinolytic potential from fibrinolysis curves. The lag time was significantly shorter and AUC increased in Aα Arg35His patients with bovine thrombin as compared with human thrombin. The MaxAbs and AUCp were significantly higher in γArg301His patients with bovine thrombin compared with human thrombin. Fibrin polymerization parameters of patients' samples were closer to those of control when assessed with TF compared with both human and bovine thrombin. T50 and overall fibrinolytic potential were similar in all samples regardless of the coagulation trigger used, however, with TF the AUCf of Aα Arg35His and γ Arg301His groups were significantly decreased compared with control. Bovine and human thrombin cannot be used equally for studying fibrin polymerization in hotspot hereditary dysfibrinogenemia or control plasmas.
23
HGVS Recommendations for the Description of Sequence Variants: 2016 Update
Johan T. den Dunnen, Raymond Dalgleish, Donna Maglott et al. · Human Mutation · 2016 · 1.7K citations · Full text
John W. Weisel, C. Nagaswami · Biophysical Journal · 1992 · 349 citations · Full text
Guidelines on fibrinogen assays
Ian Mackie, Steven Kitchen, Samuel J. Machin et al. · British Journal of Haematology · 2003 · 294 citations · Full text